blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1871887

EP1871887 - NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  06.03.2009
Database last updated on 17.08.2024
Most recent event   Tooltip06.03.2009Application deemed to be withdrawnpublished on 08.04.2009  [2009/15]
Applicant(s)For all designated states
Board of Regents, The University of Texas System
201 West 7th Street
Austin, TX 78701 / US
[N/P]
Former [2008/01]For all designated states
Board of Regents, The University of Texas System
201 West 7th Street Austin
Texas 78701 / US
Inventor(s)01 / FANG, Bingliang
9412 Sundown Drive
Pearland, Texas 77584 / US
02 / ROTH, Jack, A.
6516 Brompton Road
Houston, Texas 77005 / US
03 / JI, LinX.
2323 Cypress Run Dr.
Sugar Land, TX 7747 / US
 [2008/01]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[N/P]
Former [2008/35]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2008/01]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date06737660.809.03.2006
[2008/01]
WO2006US08502
Priority number, dateUS20050659935P09.03.2005         Original published format: US 659935 P
[2008/01]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2006096815
Date:14.09.2006
Language:EN
[2006/37]
Type: A2 Application without search report 
No.:EP1871887
Date:02.01.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 14.09.2006 takes the place of the publication of the European patent application.
[2008/01]
Search report(s)International search report - published on:EP08.03.2007
ClassificationIPC:C12N15/67
[2008/01]
CPC:
A61K48/0058 (EP,US); C12N15/10 (KR); A61P35/00 (EP);
A61P35/02 (EP); C12N15/09 (KR); C12N15/64 (KR);
C12N15/85 (EP,US); C12N15/86 (EP,US); C12N2710/10343 (EP,US);
C12N2830/008 (EP,US); C12N2830/15 (EP,US); C12N2830/60 (EP,US);
C12N2830/85 (EP,US); C12N2840/20 (EP,US); C12N2840/203 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/01]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:NEUARTIGER HTMC-PROMOTOR UND VEKTOREN ZUR TUMORSELEKTIVEN UND HOCHEFFIZIENTEN EXPRESSION KREBSTHERAPEUTISCHER GENE[2008/01]
English:NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES[2008/01]
French:PROMOTEUR HTMC ET VECTEURS DESTINES A L'EXPRESSION HAUTEMENT EFFICACE ET SELECTIVE POUR UNE TUMEUR DE GENES THERAPEUTIQUES CONTRE LE CANCER[2008/01]
Entry into regional phase08.10.2007National basic fee paid 
08.10.2007Designation fee(s) paid 
08.10.2007Examination fee paid 
Examination procedure12.03.2007Request for preliminary examination filed
International Preliminary Examining Authority: EP
08.10.2007Amendment by applicant (claims and/or description)
08.10.2007Examination requested  [2008/01]
04.04.2008Despatch of a communication from the examining division (Time limit: M06)
15.10.2008Application deemed to be withdrawn, date of legal effect  [2009/15]
20.11.2008Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2009/15]
Fees paidRenewal fee
08.10.2007Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[PX]  - DAVIS JJ ET AL, "Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter", CANCER GENE THERAPY, (20060217), pages 1 - 4, XP002406383 [PX] 1-117 * see the whole document *
 [PX]  - WU G. ET AL, "A novel synthetic hTERT-Mini_CMV chimera promoter-driven tumor-selective and high-efficiency expression of transgene for systemic cancer gene therapy", PROC. AMER. ASSOC. CANCER RES., (20050401), vol. 46, page 3358, XP002406384 [PX] 1-117 * see the whole document *
 [X]  - HAGSTROM J N ET AL, "Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, (20000415), vol. 95, no. 8, ISSN 0006-4971, pages 2536 - 2542, XP002223433 [X] 1,9,10 * see the whole document *
 [X]  - OMRULLEH S ET AL, "ACTIVITY OF A CHIMERIC PROMOTER WITH THE DOUBLED CAMV 35S ENHANCER ELEMENT IN PROTOPLAST-DERIVED CELLS AND TRANSGENIC PLANTS IN MAIZE", PLANT MOLECULAR BIOLOGY, SPRINGER, DORDRECHT, NL, (1993), vol. 21, no. 3, ISSN 0167-4412, pages 415 - 428, XP001024601 [X] 1 * see abstract *

DOI:   http://dx.doi.org/10.1007/BF00028800
 [X]  - DIAZ R M ET AL, "Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma", JOURNAL OF VIROLOGY, (199801), vol. 72, no. 1, ISSN 0022-538X, pages 789 - 795, XP002406385 [X] 1 * see abstract *
 [Y]  - WANG J ET AL, "Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20030710), vol. 546, no. 2-3, ISSN 0014-5793, pages 315 - 320, XP004433665 [Y] 1-112 * see the whole document *

DOI:   http://dx.doi.org/10.1016/S0014-5793(03)00606-9
 [Y]  - FUKAZAWA TAKUYA ET AL, "Development of a cancer-targeted tissue-specific promoter system.", CANCER RESEARCH, (20040101), vol. 64, no. 1, ISSN 0008-5472, pages 363 - 369, XP002406386 [Y] 1-112 * see the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-03-2507
 [A]  - AGHA-MOHAMMADI SIAMAK ET AL, "Regulatable systems: Applications in gene therapy and replicating viruses", JOURNAL OF CLINICAL INVESTIGATION, (200005), vol. 105, no. 9, ISSN 0021-9738, pages 1177 - 1183, XP002406387

DOI:   http://dx.doi.org/10.1172/JCI10027
 [A]  - MAJUMDAR A S ET AL, "The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters", GENE THERAPY, (200104), vol. 8, no. 7, ISSN 0969-7128, pages 568 - 578, XP002406388

DOI:   http://dx.doi.org/10.1038/sj.gt.3301421
 [A]  - HORIKAWA I ET AL, "CLONING AND CHARACTERIZATION OF THE PROMOTER REGION OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE GENE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19990215), vol. 59, ISSN 0008-5472, pages 826 - 830, XP002905138
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.